Locations
England, UK · Oxford, UK · Oxfordshire, UK
industry
Biotechnology
Size
51-200 employees
Stage
Series B
founded in
2016
Omass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. Omass is backed by Syncona Ltd and Oxford Science Enterprises.
Something looks off?On-site & Remote